Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis

Abstract

Objective To evaluate trials of drugs that target amyloid to determine whether reductions in amyloid levels are likely to improve cognition. Design Instrumental variable meta-analysis. Setting 14 randomized controlled trials of drugs for the prevention or treatment of Alzheimer’s disease that targeted an amyloid mechanism, identified from ClinicalTrials.gov. Population Adults enrolled in randomized controlled trials of amyloid targeting drugs. Inclusion criteria for trials vary, but typically include adults aged 50 years or older with a diagnosis of mild cognitive impairment or Alzheimer’s disease, and amyloid positivity at baseline. Main outcome measures Analyses included trials for which information could be obtained on both change in brain amyloid levels measured with amyloid positron emission tomography and change in at least one cognitive test score reported for each randomization arm. Results Pooled results from the 14 randomized controlled trials were more precise than estimates from any single trial. The pooled estimate for the effect of reducing amyloid levels by 0.1 standardized uptake value ratio units was an improvement in the mini-mental state examination score of 0.03 (95% confidence interval −0.06 to 0.1) points. This study provides a web application that allows for the re-estimation of the results when new data become available and illustrates the magnitude of the new evidence that would be necessary to achieve a pooled estimate supporting the benefit of reducing amyloid levels. Conclusions Pooled evidence from available trials reporting both reduction in amyloid levels and change in cognition suggests that amyloid reduction strategies do not substantially improve cognition.

Aducanumab for Alzheimer’s disease?

“…Biogen submitted its reanalysis to the FDA, and together they ran several retrospective analyses to explore the discrepancy between the two trials 4. Despite extensive evidence of ineffectiveness of other anti-amyloid agents,56 the new analyses focused on explaining why one of the trials had returned a negative result, rather than exploring why the other one had not. None of these analyses found anything more persuasive than a chance result that would have “regressed to the mean” (averaged out as ineffective) had the trials continued to completion 47…”

Fulfilling the Mandate of the US Food and Drug Administration’s Accelerated Approval Pathway

“…reliability of reductions in plaques as a surrogate marker for clinical benefit. 3 In fact, at the November 2020 FDA advisory committee meeting where aducanumab was discussed, the agency explicitly discounted changes in the number of amyloid plaques as a basis for approving the drug. Moreover, the FDA's internal statistical review found no association at the patient level between changes to the surrogate marker and the clinical outcomes reported in pivotal trials.…”

Three FDA advisory panel members resign over approval of Alzheimer’s drug

“…In February research published in The BMJ pooled evidence from available trials and suggested that amyloid reduction strategies do not substantially improve cognition 5…”